TNF and inflammatory bowel disease: During the first 2 months after diagnosis, TNFα-inhibitor therapies were used in about 35% of patients [EO-CD: n = 17 (39.5%)—VEO-UC/IBD-U: n = 6 (35.3%)—EO-UC/IBD-U n = 8 (33.3%)], except in VEO-CD (27.3%).